FindTrial
Sign In

Correlation of peripheral blood F13A1 expression and super-enhancer chr6:6474317 activity with coagulation dysfunction and prognosis in patients with acute respiratory distress syndrome (ARDS)

Correlation of peripheral blood F13A1 expression and super-enhancer chr6:6474317 activity with coagulation dysfunction and prognosis in patients with acute respiratory distress syndrome (ARDS)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128892
Enrollment
Unknown
Registered
2026-07-27
Start date
2026-07-31
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome (ARDS)

Interventions

Healthy control group:None
ARDS patient group:None

Sponsors

Shandong Provincial Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. Meet the Berlin Definition of ARDS (2012); 3. Admitted to the Department of Respiratory Medicine, Emergency Department, or ICU within 24 hours; 4. Signed informed consent obtained from the patient or legal representative.

Exclusion criteria

Exclusion criteria: 1. Preexisting coagulation disorders or history of hematological diseases before admission; 2. Use of anticoagulant or antiplatelet drugs within 2 weeks before enrollment; 3. Severe liver or kidney dysfunction (Child-Pugh class C or renal failure requiring dialysis); 4. Pregnant or lactating women; 5. Expected survival time < 24 hours.

Design outcomes

Primary

MeasureTime frame
F13A1 mRNA level;Activity of super-enhancer chr6:6474317;28-day all-cause mortality.;—

Countries

China

Contacts

Public ContactShi Zhang

Shandong Provincial Third Hospital

394873967@qq.com+86 531 55865152

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026